📊 JAZZ Key Takeaways
Is Jazz Pharmaceuticals plc (JAZZ) a Good Investment?
Jazz Pharmaceuticals faces severe profitability challenges with negative operating income and net margins despite 4.9% revenue growth, indicating operational underperformance in its core business. While the company maintains adequate liquidity (1.86x current ratio) and generates strong free cash flow of $1.3B, the persistent operating losses and high leverage (1.24x debt/equity with 5.4B long-term debt) raise concerns about debt sustainability and operational viability.
Jazz Pharmaceuticals shows a split fundamental profile: modest top-line growth and very strong cash generation support the business, but the sharp swing to negative operating and net income raises concerns about earnings quality and cost structure. Liquidity appears solid and free cash flow is strong enough to support operations and debt service over time, yet elevated leverage and deeply negative interest coverage make sustained profitability recovery the key issue.
Why Buy Jazz Pharmaceuticals plc Stock? JAZZ Key Strengths
- Strong free cash flow generation of $1.3B with 30.4% FCF margin, indicating operational cash conversion remains healthy
- Solid liquidity position with $1.4B cash and 1.86x current ratio providing financial flexibility
- Revenue growth of 4.9% YoY shows maintained market demand despite operational challenges
- Significant insider activity with 26 Form 4 filings suggesting management engagement
- Strong free cash flow generation with $1.30B of FCF and a 30.4% FCF margin
- Solid liquidity profile with a 1.86x current ratio and $1.39B in cash
- Revenue is still growing year over year, indicating underlying commercial demand remains intact
JAZZ Stock Risks: Jazz Pharmaceuticals plc Investment Risks
- Severe profitability deterioration with operating income of -$430.2M and net loss of -$356.1M, indicating operational distress
- Negative gross margin conversion at 14.3% gross margin with -10.1% operating margin suggests fundamental pricing or cost structure problems
- High financial leverage with $5.4B long-term debt against $4.3B equity and negative interest coverage of -13.1x creates debt sustainability risk
- Negative ROE of -8.2% and ROA of -3.1% demonstrate destruction of shareholder capital and inefficient asset utilization
- Profitability deteriorated sharply, with negative operating margin, net margin, and EPS
- High leverage with $5.36B of long-term debt and 1.24x debt-to-equity
- Negative interest coverage suggests current earnings do not adequately support financing costs
Key Metrics to Watch
- Operating margin trend and path to profitability - critical to assess turnaround viability
- Debt service capability given negative operating income and reliance on FCF to cover interest obligations
- Gross margin expansion potential indicating whether cost structure improvements are achievable
- Cash burn rate and runway given sustained operating losses despite positive FCF
- Operating margin recovery and net income normalization
- Free cash flow durability relative to debt reduction and interest burden
Jazz Pharmaceuticals plc (JAZZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 30.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
JAZZ Profit Margin, ROE & Profitability Analysis
JAZZ vs Healthcare Sector: How Jazz Pharmaceuticals plc Compares
How Jazz Pharmaceuticals plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jazz Pharmaceuticals plc Stock Overvalued? JAZZ Valuation Analysis 2026
Based on fundamental analysis, Jazz Pharmaceuticals plc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jazz Pharmaceuticals plc Balance Sheet: JAZZ Debt, Cash & Liquidity
JAZZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jazz Pharmaceuticals plc's revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $6.10 reflects profitable operations.
JAZZ Revenue Growth, EPS Growth & YoY Performance
JAZZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1B | -$14.6M | $3.42 |
| Q2 2025 | $1.0B | -$14.6M | $2.35 |
| Q1 2025 | $897.8M | -$14.6M | $-0.23 |
| Q3 2024 | $972.1M | -$14.6M | $2.14 |
| Q2 2024 | $957.3M | -$14.6M | $1.52 |
| Q1 2024 | $892.8M | -$14.6M | $-0.23 |
| Q3 2023 | $940.7M | $1.6M | $0.26 |
| Q2 2023 | $932.9M | $1.6M | $0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Jazz Pharmaceuticals plc Dividends, Buybacks & Capital Allocation
JAZZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jazz Pharmaceuticals plc (CIK: 0001232524)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JAZZ
What is the AI rating for JAZZ?
Jazz Pharmaceuticals plc (JAZZ) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JAZZ's key strengths?
Claude: Strong free cash flow generation of $1.3B with 30.4% FCF margin, indicating operational cash conversion remains healthy. Solid liquidity position with $1.4B cash and 1.86x current ratio providing financial flexibility. ChatGPT: Strong free cash flow generation with $1.30B of FCF and a 30.4% FCF margin. Solid liquidity profile with a 1.86x current ratio and $1.39B in cash.
What are the risks of investing in JAZZ?
Claude: Severe profitability deterioration with operating income of -$430.2M and net loss of -$356.1M, indicating operational distress. Negative gross margin conversion at 14.3% gross margin with -10.1% operating margin suggests fundamental pricing or cost structure problems. ChatGPT: Profitability deteriorated sharply, with negative operating margin, net margin, and EPS. High leverage with $5.36B of long-term debt and 1.24x debt-to-equity.
What is JAZZ's revenue and growth?
Jazz Pharmaceuticals plc reported revenue of $4.3B.
Does JAZZ pay dividends?
Jazz Pharmaceuticals plc does not currently pay dividends.
Where can I find JAZZ SEC filings?
Official SEC filings for Jazz Pharmaceuticals plc (CIK: 0001232524) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JAZZ's EPS?
Jazz Pharmaceuticals plc has a diluted EPS of $-5.84.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JAZZ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Jazz Pharmaceuticals plc has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JAZZ stock overvalued or undervalued?
Valuation metrics for JAZZ: ROE of -8.2% (sector avg: 15%), net margin of -8.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JAZZ stock in 2026?
Our dual AI analysis gives Jazz Pharmaceuticals plc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JAZZ's free cash flow?
Jazz Pharmaceuticals plc's operating cash flow is $1.4B, with capital expenditures of $58.8M. FCF margin is 30.4%.
How does JAZZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.3% (avg: 12%), ROE -8.2% (avg: 15%), current ratio 1.86 (avg: 2).